KMT2A‐r leukemias are known to have dysregulated transcription secondary to hypermethylated gene signatures, which can be restored by epigenetic agents such as DNA methyltransferase inhibitors (DNMTis) (e.g., azacytidine [AZA] and decitabine [11]) and histone deacetylase inhibitors (HDACis) (e.g., vorinostat). This evidence concerns the gene KMT2A and leukemia.